HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

Posted by Stanley Muller on May 18th, 2026

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $120.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 93.77% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Thursday. UBS Group boosted their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Finally, Barclays boosted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and an average target price of $120.80.

View Our Latest Analysis on ORKA

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $61.93 on Monday. The company’s 50 day simple moving average is $55.17 and its 200-day simple moving average is $39.42. The company has a market capitalization of $3.73 billion, a price-to-earnings ratio of -31.92 and a beta of -0.20. Oruka Therapeutics has a 1 year low of $9.40 and a 1 year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Equities analysts expect that Oruka Therapeutics will post -2.15 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,641 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. This represents a 18.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,765 shares of company stock worth $1,522,695. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Fairmount Funds Management LLC grew its position in shares of Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after buying an additional 333,340 shares during the last quarter. Viking Global Investors LP purchased a new position in Oruka Therapeutics during the 3rd quarter worth approximately $51,280,000. Deep Track Capital LP grew its stake in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares during the last quarter. Vanguard Group Inc. grew its stake in Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after buying an additional 676,865 shares during the last quarter. Finally, RTW Investments LP grew its stake in Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after buying an additional 112,499 shares during the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.